Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children

Página do item simplificado
dc.citation.issue4]
dc.citation.volume80]
dc.contributor.authorLiendo, Vera Lucia [UNIFESP]
dc.contributor.authorVola, Maria Eugenia [UNIFESP]
dc.contributor.authorBarreiro, Telma Pereira [UNIFESP]
dc.contributor.authorWakamatsu, Tais Hitomi UNIFESP]
dc.contributor.authorPereira Gomes, Jose Alvaro [UNIFESP]
dc.contributor.authordos Santos, Myrna Serapiao [UNIFESP]
dc.coverageSao Paulo
dc.date.accessioned2020-06-26T16:30:22Z
dc.date.available2020-06-26T16:30:22Z
dc.date.issued2017
dc.description.abstractPurpose: Administration of eye drops containing antihistamines or sodium cromoglycate and its derivatives for the treatment of allergic keratoconjunctivitis is often insufficient and usually requires the addition of corticosteroids. However, the risk of complications, such as glaucoma and cataract, limits the use of corticosteroids to short courses, resulting in inadequate long-term treatment response. Immunosuppressive drugs have been considered as a valid alternative to steroids for atopic keratoconjunctivitis and vernal keratoconjunctivitis. This study aimed to evaluate the use of topical tacrolimus (TCL) in improving the clinical signs of severe allergic keratoconjuctivitis in children. Methods: Patients with severe allergic keratoconjunctivitis associated with corneal epitheliopathy, gelatinous limbal infiltrates, and/or papillary reaction, along with a history of recurrences and resistance to conventional topical anti-allergy agents, were included in this open clinical trial. Patients were treated with 0.03% TCL ointment for ocular use. A severity score ranging from 0 to 9, with 9 being the highest and 0 being the lowest, was assigned based on signs observed on biomicroscopy prior to and following TCL treatment. Results: Analyses included 66 eyes of 33 patients. After a mean follow-up period of 13 months (range, 12-29 months), TCL treatment significantly decreased the mean symptom score severity for the right (from 5.56 +/- 1.18 to 2.76 +/- 1.5en
dc.description.abstractp<0.001) and left (from 5.94 +/- 1.16 to 2.86 +/- 1.64en
dc.description.abstractp<0.001). Conclusion: Topical TCL was effective and significantly improved the clinical signs of allergic keratoconjuctivitis in children. Thus, it is a potential new option for severe and challenging cases of ocular allergy.en
dc.description.affiliationUniv Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, SP, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, SP, Brazil
dc.description.sourceWeb of Science
dc.format.extent211-214
dc.identifierhttps://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492017000400211&lng=en&nrm=iso&tlng=en]
dc.identifier.citationArquivos Brasileiros De Oftalmologia. Sao Paulo, v. 80, n. 4, p. 211-214, 2017.
dc.identifier.doi10.5935/0004-2749.20170052
dc.identifier.fileS0004-27492017000400211.pdf
dc.identifier.issn0004-2749
dc.identifier.scieloS0004-27492017000400211
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/53506
dc.identifier.wosWOS:000411799900002
dc.language.isoeng
dc.publisherConsel Brasil Oftalmologia
dc.relation.ispartofArquivos Brasileiros De Oftalmologia
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCorneaen
dc.subjectTacrolimus therapyen
dc.subjectConjunctivitisen
dc.subjectAllergic drug therapyen
dc.titleTopical tacrolimus for the treatment of severe allergic keratoconjunctivitis in childrenen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S0004-27492017000400211.pdf
Tamanho:
333.03 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos